<DOC>
	<DOCNO>NCT02927353</DOCNO>
	<brief_summary>To determine pharmacokinetic bioequivalence DMB-3113 adalimumab confirm safety study drug healthy Japanese adult male subject</brief_summary>
	<brief_title>A Phase 1 Pharmacokinetic Bioequivalence Study DMB-3113 Adalimumab Healthy Japanese Adult Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Healthy Japanese male adult ; 2 . The Body Mass Index ( BMI ) subject must 17.6 26.4 kg/m2 time screen test ; 3 . Subjects must take screen test within 4 week date administration study drug ; subject must take screen test date administration study drug exhibit clinically abnormal finding judgment investigator subinvestigators 1 . Concurrent history potentially fatal infection opportunistic infection , include sepsis , pneumonia , fungal infection ; 2 . Individuals history tuberculosis diagnose tuberculosis interview , chest Xray examination , interferongamma release assay ; 3 . Concurrent history demyelinate disease ( multiple sclerosis , etc . ) ; 4 . Concurrent history congestive cardiac failure ; 5 . Concurrent history allergic symptom asthma bronchial , druginduced rash , urticaria , , judgment investigator subinvestigators , may affect participation clinical study ; 6 . Concurrent history cardiac , hepatic , renal , gastrointestinal , respiratory , and/or hematological function disorder , , judgment investigator subinvestigators , may affect participation clinical study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bioequivalence , Biosimilarity , Pharmacokinetics , adalimumab</keyword>
</DOC>